Related News

FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
RIDGEFIELD, Conn., Feb. 22 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole ... 
22 Feb 2010
Business News, Clinical Trial News
UCSF Enters Drug Discovery Agreement with Genentech
February 18, 2010 -- The University of California, San Francisco has signed a partnership agreement with Genentech, Inc., a wholly owned member of the Roche Group, to discover and develop drug ... 
19 Feb 2010
Business News, Research News
Neurologix Gene Therapy for Parkinson's Disease Phase II Trial Results in 2010
Summary Neurologix, Inc.   initiated the 44 patient Phase II trial in December 2008, and completed the surgical portion of their multi-center, controlled, double-blinded assessment of ... 
15 Feb 2010
Clinical Trial News
Synosia Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson’s Disease
BASEL, Switzerland–(BUSINESS WIRE)– Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in ... 
01 Feb 2010
Business News
MJFF Awards $2.1 Million to Drive Six Industry Teams' Pre-clinical Development of Neuroprotective Parkinson's Therapies
As part of its mission to speed development of transformative treatments for Parkinson’s disease, The Michael J. Fox Foundation for Parkinson’s Research announced a total of $2.1 million ... 
19 Jan 2010
Funding News
New study investigating Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease
A recent report in the Archives of Neurology investigates dopamine agonist withdrawl in Parkinson's patients. The authors show a subset of patients (19% - 5 of the 26 who underwent DA taper) ... 
14 Jan 2010
Research News
Responses: 1
Parkinson's Disease Society Announces 2010 Innovation Grants
The Parkinson's Disease Society (PDS) invests in bold new ideas that have the potential to transform the lives of people with Parkinson's. Innovation grants support exceptionally innovative research ... 
07 Jan 2010
Funding News
Responses: 1
Request for Information: Soliciting Input on Huntington’s Disease Best Practice Guidelines for Therapeutic Target Validation
This is a time-sensitive Request for Information (RFI) issued by the National Institute of Neurological Disorders and Stroke. The purpose of this RFI is to solicit recommendations on the best ... 
05 Jan 2010
Funding News, Government News
A Clue to Neuron Vulnerability
Published today in the Journal of Neuroscience, Dr. Carlos Paladini and colleagues get to the bottom of burst firing activity in dopaminergic neurons of the substantia nigra. Together with recent ... 
15 Dec 2009
Research News
Responses: 4
The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease Modifying Parkinson's Disease Treatments
NEW YORK, November 30, 2009 — The Michael J. Fox Foundation for Parkinson’s Research (MJFF) today announced $1.5 million in total awards to six research teams working to develop ... 
30 Nov 2009
Funding News, MJFF Funded Projects: Abstracts, Progress, and Outcomes